



Journal of Hospital Pharmacy
An Official Publication of Bureau for Health & Education Status Upliftment
(Constitutionally Entitled as Health-Education, Bureau)

A Review on Exploring the Anticancer Potential of Fluphenazine: A Study on Its Efficacy against Human Cancer Cells

Prajwal Aher^{1}, Dr. Bhavesh Akbari¹*

¹Department of Pharmaceutics, School of Pharmacy, P. P. Savani University, Dhamdod, Kosamba, Surat District, Gujrat India 394125

^{1*}Corresponding Author: Prajwal Rajan Aher, Research Scholar, School of Pharmacy, P. P. Savani University, Dhamdod, Kosamba, Surat District, Gujrat India 394125

Email Id: servicheb@gmail.com

Abstract:

A tactic called "drug repurposing" can expedite and discover new therapeutic applications for medications that have previously received approval for a number of illnesses, including cancer. When compared to the creation of novel medications, this process is expedited because these substances have previously undergone clinical trial testing and since information regarding their pharmacokinetics has already been published, the expenses and time involved in creating novel anticancer treatments are decreased. According to multiple studies, fluphenazine has the potential to be repurposed as a cancer therapeutic because it has been shown to decrease the viability of various cancer cell lines. Comprehensive literature research on the anticancer properties of fluphenazine in various human cancer cells was done for review. Several research articles have been found. This review summarizes the key findings from studies which shows the cytotoxic effect of the drug fluphenazine in lungs, breasts, colons, liver, brain, leukaemia, oral, ovarian, and types of skin cancers.

Keywords: Anti-psychotic, Fluphenazine, Anti-Cancer, multidrug resistance (MDR), dipalmitoylphosphatidylcholine (DPPC), parallel reaction monitoring (prm), Toll-like receptor 3 (TLR3)

Access this Article Online	Quick Response Code: 
Website: http://www.journalofhospitalpharmacy.in	
Received on 28/06/2025	
Accepted on 12/07/2025 © HEB All rights reserved	